English
This article is from Advanced Biomedical Research , volume 3 . Abstract Background:: Increased apolipoprotein B100 (apo B) and decreased apolipoprotein A-I (apo A-I) production are important risk factors in atherosclerosis. Urotensin II (UII), as the most potent vasoconstrictor in human, is related with hypertension and probably atherosclerosis. Because of the relationship between the hypertension and lipoprotein metabolism in atherosclerosis, the aim of this study was to test the effect of urotensin II on apo B and apo A-I expression in hepatic (HepG2) cell line. Materials and Methods:: HepG2 cells were treated with 10, 50, 100, and 200 nmol/L of urotensin II (n = 6). Relative apo B and apo A-I messenger RNA (mRNA) levels in conditioned media, normalized to glyceraldehyde-3-phosphate dehydrogenase, were measured with quantitative real-time polymerase chain reaction method. In addition, apo B and apo A-I levels were also estimated and compared with the controls using the western blotting method. Data were analyzed statistically by ANOVA and non-parametric tests. Results:: The apo B mRNA levels were not increased significantly following the treatment with UII. However, apo B protein
Sign in with your free account to read, download EPUBs or listen.
Ebook · Effect of urotensin II on apolipoprotein B100 and apolipoprotein A-I expression in HepG2 cell line. · Mohammadi, Abbas, Najar, Ahmad Gholamhoseinian, Khoshi, Amirhosein · Internet Archive